The development of the PASTEUR curriculum will be enhanced by four related collaborations.

1. CIMIT
The Center for Innovative Minimally Invasive Therapy (CIMIT) is a multi-institute collaborative program that seeks to unite investigations from government, academia, and industry in effort to discover, develop, and evaluate new approaches and technologies in minimally invasive diagnosis and treatment. We feel strongly that the clinical investigator of the future will frequently rely upon these technologies - in some cases, actually developing or adapting them; consequently, it is critical for medical students considering careers in patient-oriented investigation to develop a familiarity with the opportunities minimally-invasive technology affords.
Contact person: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

2. Clinical Research Program (CRP)
The Massachusetts General Hospital's Clinical Research Program (CRP) is an academic and service organization established to encourage the growth of clinical research. The CRP is under the direction of Dr. William Crowley.
The program's mandate is to
(1) enhance bench to bedside research;
(2) train clinical investigators; and
(3) facilitate clinical trial activity.
Additional information may be found at the CRP website.
Contact person: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

3. Center for Medical Simulation
The Center for Medical Simulation (CMS) is an educational organization dedicated to improving the quality of health care through dynamic teaching tools. CMS specializes in the use of high-fidelity patient simulators to allow realistic " practice " without risk.
The PASTEUR contact person for the CMS is This e-mail address is being protected from spam bots, you need JavaScript enabled to view it , additional information about the CMS may be found at: www.harvardmedsim.org.

4. Industrial Partners
Industry represents a critical intellectual partner in our efforts to design and implement a curriculum in patient-oriented research. We believe it is vital for future clinical investigators to develop as broad a perspective as possible, a perspective that incorporates not only the view from within academic health centers, but also the somewhat different view from within industry. We feel that students would particularly benefit from the expertise of industry in the following four areas:

• Development of team approaches to problem solving
• Development and use of surrogate markers and endpoints
• Application and implementation of high-throughput strategies
• Consideration of the impact of the human genome project on future genotype/phenotype studies and on clinical trials

Current industrial collaborators include:

• GlaxoSmithKline
  Contact person: Dr. Peter Traber (Bio available soon)
• Merck
  Contact person: Dr. Barry J. Gertz (Bio)
• Novartis
  Contact person: Dr. David R. Parkinson (Bio)
• Pharmacia
  Contact persons: Dr. Donald C. Anderson (Bio), Dr. Roy Bullingham (Bio), and Dr. Philip F. Vonvoigtlander (Bio)